A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

NCT04881994 | Completed Phase 1

• 2 other identifiers: 145102013-005089-21
• Study Type: interventional
• Target: 27
• Locations: 1 country
• Sites: 1

Brief Summary

Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should, as well as to treat patients who have diabetic nephropathy, a long-term, progressive decrease in the kidneys' ability to work properly in patients with diabetes mellitus. In this study researchers wanted to learn more about a new substance called finerenone (BAY94-8862). Finerenone is a substance that blocks the activation of a protein in the body called mineralocorticoid receptor (MR). An increased activation of MR is involved in the development of hypertension, organ damage and worsening of heart failure. The researchers studied how finerenone moves into, through and out of the body. The researchers also looked at how safe finerenone is and how it affects the body. The main purpose of this study was to help researchers develop recommendations for the amount of the substance (the dosing) to be given to patients with reduced liver function.

Conditions

Worsening Chronic Heart Failure; Diabetic Nephropathy

Keywords

Child Pugh A; Child Pugh B; Liver impairment

Outcome Measures

Primary Outcomes (4)

• Area under the concentration versus time curve from zero to infinity (AUC) of finerenone in plasma

  0 hour pre-dose to 96 hour post-dose

• Area under the concentration versus time curve from zero to infinity of unbound finerenone (AUCu) in plasma

  0 hour pre-dose to 96 hour post-dose

• Maximum observed drug concentration (Cmax) of finerenone in plasma

  0 hour pre-dose to 96 hour post-dose

• Maximum observed drug concentration of unbound finerenone (Cmax,u) in plasma

  0 hour pre-dose to 96 hour post-dose

Secondary Outcomes (1)

• Number of participants with adverse events

  From the start of study treatment up to 3 days after study treatment

Other Outcomes (5)

• Percentage of fraction of free (unbound) (fu) finerenone in plasma

  1 hour post-dose

• Area under the concentration versus time curve from zero to infinity divided by dose per kilogram body weight (AUCnorm) of finerenone in plasma

  0 hour pre-dose to 96 hour post-dose

• Maximum observed drug concentration divided by dose per kilogram body weight (Cmax,norm) of finerenone in plasma

  0 hour pre-dose to 96 hour post-dose

Study Arms (3)

Mild hepatic impairment (Child Pugh A)

EXPERIMENTAL

Participants with mild hepatic impairment (Child Pugh A) received single oral dose of finerenone.

Drug: Finerenone (BAY94-8862)

Moderate hepatic impairment (Child Pugh B)

EXPERIMENTAL

Participants with moderate hepatic impairment (Child Pugh B) received single oral dose of finerenone.

Drug: Finerenone (BAY94-8862)

Healthy participants

EXPERIMENTAL

Healthy age-, weight-, and gender- matched participants received single oral dose of finerenone.

Drug: Finerenone (BAY94-8862)

Interventions

Finerenone (BAY94-8862) DRUG

Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.

Healthy participants; Mild hepatic impairment (Child Pugh A); Moderate hepatic impairment (Child Pugh B)

Eligibility Criteria

• Age: 18 Years - 79 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All participants
• The informed consent must be signed before any study specific tests or procedures are done;
• Male and female white participants;
• Women of childbearing potential can only be included in the study if a pregnancy test is negative. Women of childbearing potential must agree to use adequate contraception when sexually active. 'Adequate contraception' is defined as any combination of at least 2 effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices). This applies from signing the informed consent form until follow up visit.
• Body mass index (BMI): 18 to 34 kg/m2 (both inclusive);
• Age: 18 to 79 years (both inclusive) at the screening visit;
• Men must agree to use adequate contraception when being sexually active. This applies from signing of the informed consent until 12 weeks after the last study drug administration. 'Adequate contraception' is defined as any combination of at least 2 effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices);
• Ability to understand and follow study-related instructions.
• Participants with hepatic impairment
• Participants with documented liver cirrhosis confirmed by histopathology, e.g., previous liver biopsy, laparoscopy, ultrasound, or fibroscan;
• Participants with hepatic impairment (Child Pugh A or B);
• Participants with stable liver disease in the last 2 months.
• Healthy participants
• Healthy male and female white participants;
• Mean age and body weight in the control group and in the two groups with hepatic impairment (Child Pugh A and B) should not vary by more than +/-10 years and +/-10 kg;

You may not qualify if:

• All participants
• Participants with a medical disorder, condition, or history of such that would impair the participant's ability to participate or complete this study in the opinion of the investigator or the sponsor;
• Medical history of Kock pouch (ileostomy after proctocolectomy);
• Febrile illness within 1 week prior to admission to study center;
• Relevant diseases within the last 4 weeks prior to admission;
• Known severe allergies, non-allergic drug reactions, or multiple drug allergies;
• Known hypersensitivity to the study drugs;
• Participants with diagnosed malignancy within the past 5 years;
• Participants with psychiatric disorders which may disable the participants to consent;
• Use of the following co-medications from 2 weeks before until 4 days after study drug administration:
• CYP3A4 inducers (e.g. St. John´s wort, rifampicin, carbamazepin, phenytoin, phenobarbital, bosentan, efavirenz, etravirine, nevirapine)
• weak to moderate CYP3A4 inhibitors (e.g. grapefruit juice and other grapefruit containing products, erythromycin, saquinavir, amiodarone, verapamil, fluconazole, diltiazem)
• strong inhibitors of CYP3A4 (e.g. itraconazole, ketoconazol, posaconazole, voriconazole, atazanavir, ritonavir, nelfinavir or other inhibitors of human immunodeficiency virus (HIV) protease, clarithromycin, telithromycin, nefazodon, telaprevir, boceprevir) or
• gemfibrozil (a strong inhibitor of CYP2C8)
• Positive urine drug screening;

Sponsors & Collaborators

• Bayer: lead

Study Sites (1)

Unknown Facility

Kiel, Schleswig-Holstein, 24105, Germany

Location

Related Publications (1)

• Heinig R, Lambelet M, Nagelschmitz J, Alatrach A, Halabi A. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment. Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):619-628. doi: 10.1007/s13318-019-00547-x.

  PMID: 30825073 RESULT

Related Links

• Click here to find results for studies related to Bayer products.

MeSH Terms

Conditions

Diabetic Nephropathies

Interventions

finerenone

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 6, 2021
• First Posted: May 11, 2021
• Study Start: March 25, 2014
• Primary Completion: September 16, 2014
• Study Completion: December 8, 2014
• Last Updated: July 16, 2021

Record last verified: 2021-07

Data Sharing

• IPD Sharing: Will not share

Locations

DE (1)